| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00895414 | Breast Cancer | Drug: doxorubicin hydrochloride|Drug: enalapril maleate | Masonic Cancer Center, University of Minnesota | | 2009-04-01 | 2015-04-23 |
| NCT00794885 | Primary Hypertension | Drug: Enalapril/folic acid|Drug: Enalapril maleate | Shenzhen Ausa Pharmed Co.,Ltd|Anhui Medical University | Phase 4 | 2008-05-01 | 2014-08-11 |
| NCT01822639 | Hypertension | Drug: GSK2944404 FDC|Drug: Amlodipine 5 mg|Drug: Enalapril Maleate 20 mg | GlaxoSmithKline | Phase 1 | 2013-04-01 | 2016-11-18 |
| NCT00741156 | Hypertension|Congestive Cardiomyopathy | Drug: Enalaprilat | The Hospital for Sick Children | Phase 3 | 2008-07-01 | 2015-11-16 |
| NCT02252692 | Heart Failure | Drug: Enalapril | Ethicare GmbH|European Commission | Phase 1 | 2014-08-01 | 2014-09-26 |
| NCT02652728 | Heart Failure|Dilated Cardiomyopathy | Drug: Enalapril Orodispersible Minitablet | Ethicare GmbH | Phase 2|Phase 3 | 2016-01-01 | 2016-01-08 |
| NCT02652741 | Heart Failure|Congenital Heart Disease | Drug: Enalapril Orodispersible Minitablet | Ethicare GmbH | Phase 2|Phase 3 | 2016-01-01 | 2016-01-08 |
| NCT02654678 | Heart Failure|Dilated Cardiomyopathy|Congenital Heart Disease | Drug: Enalapril Orodispersible Minitablet | Ethicare GmbH | Phase 2|Phase 3 | 2016-03-01 | 2016-01-12 |
| NCT01871740 | Hypertension|Hyperhomocysteinemia | Drug: Enalapril maleate and folic acid tablets|Drug: Enalapril maleate | Shenzhen Ausa Pharmed Co.,Ltd|Nanfang Hospital of Southern Medical University | Phase 4 | 2008-05-01 | 2016-01-18 |
| NCT01115946 | Healthy|Pharmacokinetics of Enalapril | Drug: ASP1585|Drug: enalapril | Astellas Pharma Inc | Phase 1 | 2010-03-01 | 2010-05-26 |
| NCT00302705 | Hypertension | Drug: Valsartan, Enalapril|Device: Ambulatory blood pressure monitoring|Procedure: Missing one dose | University of Vigo|Hospital Clinico Universitario de Santiago|Novartis | Phase 4 | 2005-01-01 | 2009-01-02 |
| NCT03051282 | Healthy Volunteers | Drug: Enalapril | University of Michigan | Phase 4 | 2017-02-28 | 2017-02-09 |
| NCT01035255 | Heart Failure With Reduced Ejection Fraction | Drug: LCZ696 200 mg BID|Drug: Enalapril 10 mg BID | Novartis Pharmaceuticals|Novartis | Phase 3 | 2009-12-01 | 2016-07-13 |
| NCT00853658 | Chronic Heart Failure | Drug: Enalapril|Drug: Aliskiren | Novartis Pharmaceuticals|Novartis | Phase 3 | 2009-03-01 | 2016-10-03 |
| NCT02900378 | Chronic Heart Failure With Reduced Ejection Fraction | Drug: LCZ696 (sacubitril/valsartan)|Drug: Placebo to LCZ696 (sacubitril/valsartan)|Drug: Enalapril|Drug: Placebo to enalapril | Novartis Pharmaceuticals|Novartis | Phase 3 | 2016-12-01 | 2017-01-04 |
| NCT01117038 | Erectile Dysfunction | Drug: avanafil and enalapril|Drug: avanafil and amlodipine | VIVUS, Inc. | Phase 1 | 2010-04-01 | 2011-08-09 |
| NCT02768298 | Chronic Heart Failure With Reduced Ejection Fraction | Drug: LCZ696|Drug: enalapril|Drug: Enalapril matching placebo|Drug: LCZ696 matching placebo | Novartis Pharmaceuticals|Novartis | Phase 4 | 2016-07-01 | 2017-01-03 |
| NCT00520247 | Plasma Total Homocysteine Level|Blood Pressure | Drug: enalapril plus folic acid | Anhui Medical University|Peking University First Hospital|Huashan Hospital|Harbin Medical University|China Medical University Hospital|First Affiliated Hospital Xi'an Jiaotong University|Nanjing Medical University | Phase 2 | 2005-09-01 | 2007-08-22 |
| NCT02554890 | Acute Heart Failure | Drug: sacubitril/valsartan (LCZ696)|Drug: Enalapril|Drug: sacubitril/valsartan (LCZ696) matching placebo|Drug: enalapril matching placebo | Novartis Pharmaceuticals|Novartis | Phase 4 | 2016-04-01 | 2017-03-07 |
| NCT02135263 | Carboxylesterase 1 (CES1) Genotype|CES1 Activity | Drug: Methylphenidate|Drug: Enalapril | Bispebjerg Hospital|The Ministry of Science, Technology and Innovation, Denmark|Mental Health Centre Sct. Hans (Denmark)|University of Copenhagen|The Leiden Academic Center for Drug Research (LACDR)|Duke University | Phase 4 | 2012-04-01 | 2014-07-29 |
